---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-289550"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T17:22:17.715538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya partners with Dr. Reddy's on COYA 302 for ALS; raises $26.5M in private placement

## Summary
- Upfront $7.5M from Dr. Reddy's; additional $4.2M upon IND acceptance and $4.2M upon first patient in Phase 2.
- Potential development milestones up to $40M and sales milestones up to $677.25M; royalties in low to mid-teens.
- Private placement of 4.37M shares at $6.06/share for gross proceeds ~$26.5M; expected to close Dec 11, 2023.
- Former US Secretary Wilbur Ross participating in placement; expected to join board after closing.
- COYA to lead clinical development and US regulatory for COYA 302; IND filing expected in H1 2024.

## SEC filing metadata
- accession: 0001193125-23-289550
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312523289550/0001193125-23-289550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312523289550/d628270d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-289550
- JSON: https://secwatch.observer/filing/0001193125-23-289550.json
- Plain text: https://secwatch.observer/filing/0001193125-23-289550.txt

## Key facts
- Material Agreements
  Coya Therapeutics, Inc. entered into DRL Development Agreement with Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA (effective 2023-12-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA
  - Effective: 2023-12-05
  source text: On December 5, 2023, Coya Therapeutics, Inc. (the “Company”) entered into a Development and License Agreement (the “DRL Development Agreement”) with Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA (collectively, “Dr. Reddy’s”), pursuant to which, among other things, the Company granted to Dr. Reddy’s an exclusive license to commercialize COYA 302
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312523289550/0001193125-23-289550-index.htm
- Material Agreements
  Coya Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $26.5 million (effective 2023-12-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $26.5 million
  - Effective: 2023-12-05
  source text: On December 5, 2023, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of 4,370,382 shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312523289550/0001193125-23-289550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.